Introduction: Teriflunomide, indicated for the treatment of relapsing-remitting multiple sclerosis, is contraindicated in pregnancy based on signs of developmental toxicity in the offspring of rats and rabbits; developmental toxicity has also been observed in preclinical studies of other disease-modifying therapies. Despite the requirement to use reliable contraception in clinical trials evaluating the safety and efficacy of teriflunomide, a number of pregnancies have been reported. This work reports pregnancy outcomes in teriflunomide clinical trials. Methods: Pregnancy outcomes were evaluated in a retrospective analysis of the global pharmacovigilance database. The following information was collected from the pharmacovigilance database or individual patient files: treatment allocation, pregnancy outcome, teriflunomide exposure, and use of the accelerated elimination procedure. Results: At data cut-off, 83 pregnancies were reported in female patients and 22 pregnancies were documented in partners of male patients.
INTRODUCTION
In patients with multiple sclerosis (MS), diagnosis typically occurs during childbearing years [1, 2] . Consequently, it is important to understand potential risks during pregnancy posed by exposure to disease-modifying therapies (DMTs). MS itself does not appear to be associated with an increased risk of adverse Electronic supplementary material The online version of this article (doi:10.1007/s40120-014-0020-y) contains supplementary material, which is available to authorized users. pregnancy outcomes [1] . However, prenatal exposure to DMTs may adversely impact fetal development [3] .
Teriflunomide is a once-daily, oral immunomodulator approved for treatment of relapsing-remitting MS. Teriflunomide is contraindicated in pregnant women, or women of childbearing potential not using reliable contraception, based on the occurrence of teratogenicity and embryolethality in the offspring of teriflunomidetreated rats and rabbits [4, 5] . Importantly, in vitro teriflunomide studies showed no evidence for mutagenicity, and teriflunomide was not clastogenic in vivo [4, 5] . Preclinical studies with other oral DMTs have also shown potential teratogenic signals in rodents [3] .
Reliable contraception should be used throughout teriflunomide treatment, and women wishing to become pregnant must discontinue teriflunomide treatment [4, 5] . In the event of pregnancy, female patients must undergo an accelerated elimination procedure until teriflunomide plasma concentrations fall below 0.02 mg/L; a level, based on animal studies, predicted to have minimal risk to the fetus [4, 5] .
Despite the requirement to use reliable contraception in teriflunomide clinical trials, a number of pregnancies have been reported. Here, we present the outcomes of these pregnancies.
METHODS

Pregnancy Monitoring Procedures
Pregnant or lactating females were excluded from teriflunomide clinical trials. All patients entering trials were counseled on the potential risks of drug exposure in pregnancy and provided written consent not to become pregnant or to father a child, and to use reliable contraception. Where pregnancies were identified, patients were instructed to discontinue study treatment immediately and to start an accelerated elimination procedure [4, 5] . 
Analysis of Pregnancy Outcomes
Compliance with Ethics Guidelines
The data in this article are based on previously conducted studies, and do not involve any new studies, with human or animals subjects, performed by any of the authors.
RESULTS
At data cut-off, 83 pregnancies were reported in female patients enrolled into teriflunomide clinical trials (Table 1) . Of these, 13 pregnancies occurred in women exposed to interferon beta or placebo. Seventy pregnancies (including one twin pregnancy) were reported in women with known teriflunomide exposure; outcomes included 26 live births, 13 spontaneous abortions, and 29 induced abortions, including one abortion of two embryos. Subsequent to the last data cut-off, one ongoing pregnancy ( . 1) , was also documented. Of the 26 pregnancies exposed to teriflunomide that resulted in live births, 10 patients discontinued teriflunomide treatment and nine completed the accelerated elimination procedure before becoming aware of their pregnancy. The remaining 16 patients discontinued teriflunomide treatment a few days to 11 weeks after becoming pregnant, and 13 of these underwent the accelerated elimination procedure. The use of the accelerated elimination procedure in the vast majority of patients exposed to teriflunomide minimized exposure to the developing fetus by rapidly reducing teriflunomide plasma levels below those predicted to have any fetal risk (\0.02 mg/L) [4, 5] . Median birth weight, documented for 18 newborns, was 3.3 kg, and mean gestational age, documented in 23 cases, was 39 weeks (range 36-44 weeks). All newborns were healthy and did not have any structural or functional abnormalities at birth. The spontaneous abortion rate in teriflunomideexposed patients was 18.6%, within the range reported for the general population [6] . None of the induced abortions were performed due to defects or malformations.
Additionally, 22 pregnancies were documented in partners of male patients in the teriflunomide clinical program (Table 1) . Of these, three pregnancies occurred in women whose partners were exposed to placebo. Of the 19 pregnancies with known paternal teriflunomide exposure, outcomes included 16 live births, one spontaneous abortion, and two induced abortions. No structural defects or functional abnormalities were reported in newborns with paternal teriflunomide exposure, and there were no reports of embryo-fetal abnormalities in either of the induced abortions.
DISCUSSION
Preclinical studies of some oral DMTs have shown signals for some developmental toxicity in rodents [3] . Limited data on clinical including early pregnancy losses, reported in the general population (17-22%) [6] . These observations are supported further by evidence from prospective studies of the parent compound, leflunomide, approved for the treatment of rheumatoid arthritis (RA) since 1998 [8] . In a prospective study by the Organization of Teratology Information Specialists (OTIS), there were no significant differences in the rate of major structural defects, and no specific pattern of major or minor anomalies, in newborns of women with RA exposed to leflunomide relative to disease-matched or healthy comparator groups, with a similar rate to that in the general population [9] . This lack of a signal for teratogenicity was confirmed in a subsequent OTIS analysis [10] . In addition, leflunomide postmarketing surveillance of more than 2.4 million patientyears of exposure has not shown any teratogenic signal.
Teriflunomide has been detected at low levels in human semen [4] . However, animal studies show no evidence that teriflunomide adversely affects male fertility or damages sperm DNA [4, 5] . Although animal studies to evaluate the risk of male-mediated fetal toxicity have not been conducted, the risk of male-mediated embryo-fetal toxicity from teriflunomide treatment is considered low, with estimated plasma exposure in females from semen transfer from a male-treated patient expected to be C100 times lower than plasma exposure following oral dosing of teriflunomide 14 mg [5] .
However, to minimize any potential risk, some regulatory authorities recommend that men wishing to father a child should also discontinue teriflunomide treatment and undergo the accelerated elimination procedure [4] ; no such recommendation is made in the European labeling for teriflunomide [5] .
It is important to collect as much data as possible to determine potential adverse outcomes following DMT exposure during pregnancy. In this regard, global pregnancy registries for teriflunomide will capture prospective data from pregnancies that occur worldwide in the postmarketing setting. In North America, the independent OTIS group has established a pregnancy registry to collect prospective data for women exposed to teriflunomide during pregnancy [11] . A second registry will collect pregnancy data from patients in Europe and Australia. Fig. 1 Teriflunomide plasma concentrations following an accelerated elimination procedure. A loading dose of teriflunomide (70 mg/day for 3-4 days) was administered to achieve steady state rapidly; this was followed by a maintenance dose of teriflunomide 14 mg/day for 8-11 days. Cholestyramine [8 or 4 g, three times daily (tid)] or activated charcoal [50 g, two times daily (bid)] was administered orally for 11 days following teriflunomide treatment. Adapted with permission from Freedman [14] CONCLUSION While this investigation was not powered to detect teratogenicity, available data do not indicate any teratogenic signals in patients treated with teriflunomide. Teriflunomide has been shown to be an effective therapeutic option for patients with MS [12, 13] , including women of childbearing potential using effective contraception. 
ACKNOWLEDGMENTS
